Sepsis is a common and life-threatening condition caused by a dysregulated host immune response to infection. Given the prominent role of endothelial breakdown and dysfunction in sepsis, therefore, there is an urgent need to establish strategies to protect the endothelium and preserve microcirculatory function.
This study is a randomised clinical study investigating intravenous fluid therapy and oral imatinib therapy in healthy human volunteers exposed to intravenous lipopolysaccharide (LPS).
The objective of the study is to investigate the biological effects of fluid and imatinib therapy on LPS-induced microcirculatory dysfunction.
Healthy adult volunteers aged between 18 and 40 years of age
Informed consent to participate
Current participation in a clinical trial
Pregnant or breastfeeding
Current history of smoking
Alcohol intake > 21 units per week
Factorial
Imatinib
DrugPre-treatment with 600mg Imatinib administered 1 hour prior to intravenous LPS.
Compound sodium lactate solution
DrugTotal of 30 ml/kg administered 90 minutes following intravenous LPS. 30mls/kg (maximum volume of 2500mls) administered in two divided doses (15mls/kg) intravenously. Each bolus will be administered at a fixed rate of 999mls/hr.
Biomarkers of vascular and glycocalyx injury
Change in plasma biomarkers of vascular and glycocalyx injury including but not limited to - Hyaluronan
Biomarkers of inflammation
Change in plasma biomarkers of inflammation including but not limited to - Interleukin-6
Venous Excess Ultrasound Score
Ultrasound measure of venous congestion
B-lines
Ultrasound measure of pulmonary oedema
Click on the lead sponsor to view all of their trials.
Belfast Health and Social Care Trust
Lead sponsor
Medical Research Council
Collaborator
The Royal College of Anaesthetists
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
